32 results about "Genital tract" patented technology

The invention discloses a primer combination for identifying six genital tract pathogens and detecting drug resistance genes, a kit and application, the primer combination comprises a primer combination for identifying chlamydia trachomatis, mycoplasma genitalium, ureaplasma urealyticum, mycoplasma hominis, neisseria gonorrhoeae and trichomonas vaginalis and detecting the drug resistance genes of the six genital tract pathogens, and nucleotide sequences are shown as SEQ ID NO.1-SEQ ID NO.50. Microorganisms and related drug-resistant genes in a detection range are identified by utilizing a multiple PCR targeted three-generation sequencing method, the specificity is good, the sensitivity is high, the detection technology has important clinical significance when being applied to identification of genital tract infection pathogens, and compared with a traditional detection method, the detection flux, the coverage range and the sensitivity are higher, and detection is stable; compared with pathogenic microorganism metagenome (mNGS) detection, the method has the advantages that the detection cost is lower, and the detection sensitivity on drug-resistant genes and drug-resistant gene mutation is higher.

The invention relates to lactobacillus gasseri FMTA1121E with an effect of regulating a vaginal micro-ecological environment and application of the lactobacillus gasseri FMTA1121E. The lactobacillus gasseri FMTA1121E is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1121E is CGMCC No.34962. The lactobacillus gasseri FMTA1121E can be metabolized to generate beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide so as to regulate the genital tract environment and improve the health degree; and the bacillus subtilis has excellent bacteriostasis and sterilization effects on various common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1121E strain can be applied to preparation of preparations for preventing and treating related genital tract diseases such as vaginitis.

The application provides a primer probe composition and application thereof in detection of urogenital tract pathogens, and relates to the technical field of biology. The primer probe composition comprises a chlamydia trachomatis primer probe pair with sequences shown in SEQ ID NO:1-6; a gonococcus primer probe pair with sequences shown in SEQ ID NO:7-9; and a mycoplasma genitalium primer probe pair with sequences shown in SEQ ID NO:10-12. The primer probe pairs in the primer probe composition do not have significant cross interference, the lower limit of detection can be as low as 20 copies / reaction, 200 copies / mL, and the problem that the lower limit of detection of the urogenital tract pathogens in the prior art needs to be reduced is solved.

The invention discloses a primer probe group and a kit for joint detection of mycoplasma genitalium, ureaplasma urealyticum and chlamydia trachomatis, and belongs to the technical field of molecular biological detection. The primer probe group comprises a primer probe group A for directly detecting a mycoplasma genitalium mgpB gene, a primer probe group B for directly detecting a ureaplasma urealyticum ureB gene and a primer probe group C for directly detecting a chlamydia trachomatis ompA gene; the kit comprises a PCR (Polymerase Chain Reaction) reaction solution and the primer probe group. Nucleic acid extraction is not needed, the detection cost is greatly reduced, the experiment time is shortened, meanwhile, the specificity and accuracy are still guaranteed, meanwhile, the sensitivity is improved, and the method has wide application prospects in the fields of non-gonococcal genital tract infection main pathogen detection, infertility and prenatal and postnatal care screening and the like. And the kit has important significance on clinical diagnosis, early treatment and prevention of diseases, prevalence and the like.

In an aspect, a method for applying beta-alanine to a tissue surface is described. The method may comprise applying a composition comprising from about 0.01 % w / w to about 5.0 % w / w beta-alanine to a tissue surface. The beta-alanine may comprise between about 0.08 % w / w to about 2 % w / w. The tissue surface may be suffering from a condition. The tissue surface may be from the group consisting of epidermis, mucosal membrane, respiratory tract lining, urinary tract lining, and reproductive tract lining. In another aspect a composition may comprise from about 0.01 % w / w to about 5.0 % w / w beta-alanine; water; an emulsifying component; and a fat. The fat may be an emollient or a moisturizing component.

The invention belongs to the technical field of medical supplies, and particularly relates to an adjustable cervix uteri multi-point micro-injection device which comprises a guide cylinder, an adjusting mechanism is mounted in the guide cylinder, and an injection needle is mounted on the side, extending into a human body, of the adjusting mechanism; the other side of the adjusting mechanism is connected with the carry control mechanism, the rotation control mechanism and the deflection control mechanism through a first connecting rod, a second connecting rod and a third connecting rod. The other side of the adjusting mechanism is further connected with a connecting hose, and the other end of the connecting hose is connected with an injector. Wherein the adjusting mechanism comprises a carry mechanism, a rotating mechanism and a deflection mechanism, the situation that the device pierces other parts of the genital tract of a patient to cause injury before reaching the cervical lesion part can be avoided, and the injection needle can be deflected towards different parts through the adjusting mechanism; according to the device, the injection needle can accurately pierce a diseased region for injection under the condition that the adjustment range in the genital tract of a patient is minimum.

The invention belongs to the technical field of medicines, and discloses a gynecological bacteriostatic lotion and a preparation method and application thereof.The lotion is prepared from extracts of traditional Chinese medicinal materials such as radix sophorae flavescentis, cortex phellodendri, coptis chinensis, scutellaria baicalensis, rhizoma smilacis glabrae, cortex dictamni, fructus cnidii, areca nuts, cortex meliae, golden larch bark, lithospermum erythrorhizon, lavender, rheum officinale and honeysuckle as main raw materials, and parachloroxylenol, salicylic acid and borneol as auxiliary materials. A compound preparation with multiple effects is formed through scientific proportioning and a preparation process, the product can effectively inhibit common pathogenic bacteria such as Candida albicans, Staphylococcus aureus and Escherichia coli, shows a broad-spectrum and efficient antibacterial effect, and is small in irritation, high in safety to vaginal mucosa and genital tract environment and free of toxic and side effects. The product can maintain local micro-ecological balance and reduce inflammation recurrence while cleaning and nursing, has the advantages of long-term conditioning of a traditional Chinese medicine compound and rapid sterilization of western medicine components, and is suitable for clinical popularization and application.

The invention discloses a vaginal balance peptide derived from a vaginal microbiome and application thereof, the vaginal balance peptide can selectively inhibit lower genital tract infection pathogens, has no inhibition effect on vaginal probiotic lactobacillus, and has: (a) an amino acid sequence as shown in SEQ ID NO.1; or (b) an amino acid sequence which is obtained by substitution, deletion and / or addition of one or more amino acids of the amino acid sequence as shown in SEQ ID NO.1 and has the same function as that of SEQ ID NO.1; or (c) an amino acid sequence which has at least 85% homology with the amino acid sequence shown in SEQ ID NO.1 and has the same function as the amino acid sequence shown in SEQ ID NO.1. The balance peptide is efficient in antibiosis, specifically inhibits growth of lower genital tract infection pathogens, and has a remarkable inhibiting effect on gardnerella vaginalis, group B streptococcus, candida albicans and the like; the selectivity is high, the effect of inhibiting growth of various common vaginal probiotics lactobacillus is avoided, and the effect of balancing micro-ecology is achieved; the safety and the treatment effect are good.

The utility model relates to the technical field of animal husbandry instruments, in particular to a genital tract effusion collecting device for livestock in animal husbandry. The genital tract effusion collection device comprises an extraction part, a suction catheter used for stretching into the effusion position and a support assembly. The extraction part is provided with a storage cylinder used for containing genital tract effusion. And a piston is arranged in the storage cylinder. A connecting column is arranged at the bottom of the storage cylinder. And a suction channel is arranged in the connecting column. The side wall of the connecting column is sleeved with the suction catheter. The suction catheter is connected with the storage cylinder through the suction channel. The support assembly comprises a lantern ring and supporting legs. And the lantern ring is mounted on the side wall of the storage barrel. And the plurality of supporting legs are circularly arranged along the axis of the lantern ring. The supporting legs are connected with the side wall of the lantern ring. According to the genital tract effusion collecting device for the livestock in the animal husbandry, collection of the genital tract effusion of the livestock is achieved, the safety is improved, the difficulty of effusion extraction is reduced, and the collecting efficiency is improved.

The application discloses a primer and probe for urogenital tract microorganism detection, a kit and a use method of the kit. The primer and probe for urogenital tract microorganism detection, the kit and the use method of the kit can simultaneously detect chlamydia trachomatis, ureaplasma urealyticum and gonococcus. By using real-time fluorescent PCR amplification technology, only one nucleic acid extraction and one-step PCR detection reaction are needed. The use method of the kit is rapid, simple, specific, high in sensitivity and wide in detection range. The sensitivity can reach 400 copies / ml, the detection range is 400 copies / ml to 4.00E+09 copies / ml, and the non-chlamydia trachomatis, ureaplasma urealyticum and gonococcus pathogenic microorganisms cannot be detected, so the problem of false positive is not prone to occur.

A microbiome modulating composition and a method for producing the microbiome modulating composition are described herein. The method comprises preparing a culture from at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, passaging the culture on a glycogen carbon source to form a postbiotic ferment of the at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, and adding the postbiotic ferment to a carrier. Further disclosed is a method for treating microbial dysbiosis of an urogenital area or a skin area of a user, the method comprising applying the microbiome modulating composition to an urogenital or a skin area of a user. The disclosed methods and microbiome modulating compositions help promote the growth of healthy Lactobacillus spp. bacteria to prevent dysbiosis and other related conditions and infections.

This invention provides a composition for detecting genital tract pathogens, its preparation method, and its application, belonging to the field of nucleic acid or microbial assays or tests. The composition provided by this invention includes a forward primer, a reverse primer, and a probe targeting seven genital tract pathogens. The forward and reverse primers are used to amplify the target DNA. A blocking group is added between the i-th nucleotide and the (i+1)-th nucleotide from the 3' end of the reverse primer, where 4 ≤ i ≤ 8. The probe is labeled with a fluorescent group and a second quenching group at both ends, and a first quenching group in the middle. A portion of the probe's sequence is identical to a portion of the reverse primer's sequence. The composition provided by this invention enables multiplex qualitative detection of seven genital tract pathogens: Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma microsporum, Mycoplasma hominis, Mycoplasma genitalium, and herpes simplex virus type 2.

The application discloses a multiplex detection kit for urogenital tract infection pathogens, which can simultaneously and efficiently and accurately detect at least two of four pathogens, CT, MG, MH and NG, the minimum detection limit of the four pathogens is 400 copies / mL, and the kit is perfectly compatible with three samples, namely, non-invasive urine, male urethral secretions and female cervical secretions, and has a wide application range.

This invention provides a dual-segment, dual-color pH comparison catheter for clinical identification of premature rupture of membranes, belonging to the field of medical catheter technology. It includes a main catheter tube with a urine segment pH membrane and an amniotic fluid segment pH membrane sequentially arranged along the axial direction on the anterior outer wall of the main tube. The urine segment pH membrane has a color development range of pH 5.5-6.5, and its color change is a continuous gradient from yellow to green. This invention achieves zero-sampling detection under sterile conditions, highly integrating pH identification function into routine catheterization procedures. The pH value of urine and any potentially mixed amniotic fluid is simultaneously detected upon catheter insertion into the bladder, without the need for vaginal speculum, sampling swabs, or any form of secondary sterile opening. This design completely blocks the path of exogenous bacteria into the maternal reproductive tract at a physical level, thereby fundamentally and effectively reducing the incidence of clinically common chorioamnionitis and urinary tract infections, and improving perinatal medical safety and quality.

This invention relates to the field of in vitro diagnostics, and particularly to a combined diagnostic kit for prostate diseases. The invention provides reagents including pH, peroxidase, elastase, lecithin bodies, citric acid, zinc, and acid phosphatase under mild reaction conditions, enabling rapid differentiation of inflammatory and non-inflammatory prostatitis, benign prostatic hyperplasia, and non-prostatic genital tract infections using a single test card. Through extensive experimentation, this invention has developed a one-step reaction scheme suitable for the dry chemical determination of acid phosphatase and lecithin bodies in seminal plasma. This method eliminates the need for a stop solution, achieving a one-step reaction under mild conditions that will not cause damage to operators or fully automated instruments. The samples used are seminal plasma or semen, allowing for large sample volumes and easy acquisition, significantly improving diagnostic efficiency for doctors and patient comfort.

The invention discloses a control method for a liquid path system of a genital tract secretion analyzer. The control method comprises the following steps: 1, confirming the pure water amount of a water feeding unit, the reagent amount in a first container and the waste liquid amount of a waste liquid unit; then filling a water feeding unit and a reagent, and quantitatively adding a sample diluent into the sample by utilizing a reagent filling unit to obtain a diluted sample; the sample filling unit is used for taking a TIP head and quantitatively sucking and diluting a sample into a board card and a reaction container for several times; quantitatively filling a reaction reagent into the board card by using a reagent filling unit, and carrying out dry chemical detection; a reagent filling unit is used for quantitatively filling staining fluid into the reaction container, and the staining fluid is dropwise added to a slide for morphological detection after staining. The sample filling unit adopts a sample pump for direct filling, and the reagent filling unit adopts positive pressure filling, so that only one TIP head is needed in the detection process of each sample, on one hand, the TIP head material consumption is remarkably reduced, on the other hand, the action logic of sample pretreatment is simplified, and the detection efficiency of an instrument is improved.

The invention discloses a phycocyanin hydrogel capable of resisting endometritis and promoting vaginal flora regulation as well as a preparation method and application of the phycocyanin hydrogel. The preparation method comprises the following steps: a, adding a polylactic acid high-molecular polymer material into a sterile solvent, and performing low-temperature stirring reaction to obtain a hydrogel solution; and b, adding phycocyanin powder into the hydrogel solution prepared in the step a, and carrying out low-temperature stirring reaction to obtain the phycocyanin hydrogel. The hydrogel is phycocyanin hydrogel formed by wrapping natural phycocyanin with a polylactic acid derivative, accurate delivery in the genital tract can be achieved, and meanwhile, the anti-inflammatory and anti-apoptosis effects of phycocyanin can be fully exerted by slow release of the phycocyanin in the hydrogel; and the hydrogel can maintain an acidic environment in the vagina and regulate vaginal flora. The phycocyanin hydrogel disclosed by the invention is expected to bring a new treatment means for patients with endometritis and vaginal dysbacteriosis.

According to the kit for rapidly and quantitatively detecting the microorganisms in the genital tract and the micro-ecological evaluation method thereof provided by the invention, quantitative detection of nearly 50 different types and different types of microorganisms in the genital tract can be realized by designing a primer probe combination and improving amplification reaction conditions; according to the method, vaginal lactobacillus groups, pathogenic genital tract microorganisms, sexually transmitted microorganisms and cervix uteri microorganisms are covered, 32 kinds of microorganisms can be distinguished, main microorganisms in the genital tract are comprehensively covered, meanwhile, a corresponding micro-ecological evaluation method is designed in a matched mode, various vaginitis, sexually transmitted diseases and HPV are rapidly diagnosed, and the method has the advantages of being simple in operation, convenient to operate and high in practicability. And a basis is provided for clinical treatment and prognosis of genital tract infection.

This invention relates to the field of molecular detection technology, and particularly to the application of Trichomonas vaginalis target genes, primer-probe combinations, and kits. This invention provides a novel application of Trichomonas vaginalis target genes in the detection of Trichomonas vaginalis, and its specific primer-probe design. The primers and probes described in this invention have high specificity, exhibiting no cross-reactivity with closely related species and common pathogens of the urogenital tract. They also possess advantages such as rapid detection speed and high sensitivity, achieving detection results within 1 hour using real-time fluorescence PCR, and can detect as few as a single Trichomonas vaginalis. This invention also provides a kit with high detection sensitivity, enabling the detection of Trichomonas vaginalis even in urine samples. It can also be combined with primers and probes for Mycoplasma genitalium and / or Mycoplasma hominis to form primer-probe combinations.

This application belongs to the field of microbial technology, specifically disclosing the application of *Lactobacillus fermentum* BLF03 in anti-Candida activity. *Lactobacillus fermentum* BLF03 was deposited on November 6, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 36521. This application proposes a *Lactobacillus fermentum* BLF03 strain resistant to *Candida albicans* and *Candida krusei*, which can significantly inhibit the growth, reproduction, and hyphal transformation of *Candida albicans* and *Candida krusei* at the in vivo level, alleviate Candida-induced infection symptoms, reduce the expression level of the inflammatory marker procalcitonin (PCT) after Candida infection, improve the inflammatory stress response induced by infection, and has a significant protective effect against tissue damage caused by Candida invasion. It also has targeted preventive and adjunctive therapeutic effects on Candida infections in the urogenital tract and other sites, providing a new, safe, and highly effective strain for anti-Candida products.

The invention discloses a gel composition for repairing female genital tracts as well as a preparation process and application of the gel composition. The composition comprises three functional core systems: a polysaccharide-enzyme compound A which is formed by self-assembly of superoxide dismutase and oxidative degradation modified aloe polysaccharide and has antioxidant and microenvironment regulation functions; a metal ion-polysaccharide slow-release antibacterial body B formed by coordination of zinc ions and low-molecular-weight chitosan provides instant and long-acting antibacterial protection; the plant polyphenol-protein tissue repair body C is formed by non-covalent binding of epigallocatechin gallate and hydrolyzed collagen, and tissue regeneration and functional reconstruction are promoted. The three components are compounded according to a mass ratio of (1-2): (0.5-1): (2-4), and are integrated with a carbomer matrix to form stable gel. The invention further provides a specific preparation process and a synergistic effect mechanism of all the components. The gel has good stability, biocompatibility and repairing efficiency, and is suitable for treating or improving female genital tract mucosa lesion, inflammation or flora imbalance.

The invention focuses on a quantum dot microfluidic immunodetection chip and a kit for detecting female genital tract chlamydia trachomatis. The chip comprises a substrate and a cover plate, a sample loading area, a pretreatment area, a reaction area, a detection area and a waste liquid area which are sequentially communicated are formed on the substrate, a plurality of layers of polyelectrolyte-nano magnetic bead self-assembled films are formed in the pretreatment area, an electromagnetic coil is embedded in the cover plate and is aligned with the center of the pretreatment area, and the electromagnetic coil is embedded in the cover plate. A quantum dot anti-MOMP antibody is fixed on the inner wall of a channel of the reaction area, and a photonic crystal microcavity is formed in the detection area. The kit comprises the chip. According to the chip, rapid, high-sensitivity and high-specificity detection of CT is realized through three core innovative designs of a fluorescence enhancement region, an active in-situ pretreatment and enrichment structure and a space-time resolution antibody arrangement structure; meanwhile, a kit containing the chip is provided, the detection convenience and the automation level are further improved, and the application requirements of basic medical institutions are met.

The invention belongs to the technical field of animal models, and particularly relates to a preparation method for constructing a rat embryo implantation failure model based on streptococcus agalactiae. The method comprises the following steps: culturing a streptococcus agalactiae strain with the number of BNCC336970 by using a solid culture medium containing sheep blood, adjusting the concentration of a bacterial solution to 1 * 10 < 8 > CFU / mL, and carrying out vaginal perfusion on an SPF-grade female SD rat every day for 21 days continuously. And after the perfusion is finished, the female mouse is mated with the male mouse at the early oestrus stage, the detected vaginal suppository is marked as the 0.5 th day of pregnancy, the mouse is killed at the 7.5 th day of pregnancy, and the model is evaluated by counting the embryo implantation quantity and detecting the expression level of endometrial tissue receptivity factors MMP9 and VEGF (Vascular Endothelial Growth Factor). A clinical pathogen pathogenic mechanism is simulated through a genital tract infection way for the first time, and the problem of physiological status deviation caused by traditional hormone intervention, immune agonists or genetic engineering methods is solved. The constructed model can stably induce the obvious reduction of the embryo implantation number and the reduction of endometrial receptivity, and provides a standardized tool for the pathological mechanism research of infectious embryo implantation failure and the screening of therapeutic drugs.

The utility model relates to the technical field of kits, in particular to a cervical cancer screening kit which comprises a detection rod and detection card bodies, a plurality of cavities are formed in the detection rod, the detection card bodies are fixedly connected to the inner walls of the cavities respectively, a sampling assembly is arranged on the detection rod, and the detection card bodies are fixedly connected to the inner walls of the cavities respectively. The sampling assembly comprises grooves and through holes, the multiple grooves are formed in the detection rod, the multiple through holes are formed in the inner walls of the multiple cavities, the two ends of the multiple through holes communicate with the multiple cavities and the multiple grooves correspondingly, a driving assembly is arranged on the detection rod, the driving assembly comprises a push plate, and the push plate is arranged on the detection rod. The multiple push plates are slidably connected to the interiors of the multiple grooves correspondingly. The vagina sampling kit can be directly placed in the vagina of a user for use, so that the problem that the user inconveniently samples liquid in the genital tract is solved, the problems of sanitation and pollution can be greatly avoided, and the detection accuracy of the kit is improved.

The invention provides a nucleic acid mixed detection method for genital tract chlamydia trachomatis infection, and belongs to the technical field of pathogen detection. The method comprises the following steps: mixing a to-be-detected sample and dividing the sample into six mixed sample pools, and detecting the mixed sample to obtain a positive mixed sample and / or a negative mixed sample; and performing single sample detection on a single sample corresponding to the positive mixed sample. According to the method, 6 mixing (5: 1) is taken as the optimal mixing detection proportion, the sensitivity of mixing detection is 96.70%, and the specificity is 100%; after 9 samples are detected again, the sensitivity is improved to 98.40%, the total coincidence rate is 98.40% (95% CI: 96.5%-100%), and the accuracy requirement of chlamydia trachomatis qualitative detection registration is basically met. The mixed detection technology can increase the number of screened people and the number of positive examples by three times, can save 1 / 3 of reagent cost, and has certain hygienic economic significance.

The utility model discloses a genital tract sample collecting tube device which comprises a tube body, a tube cover and a sampling cotton swab, zirconium oxide beads are arranged in the tube body, a flaring section is arranged at the top of the tube body, external threads are arranged outside the flaring section, the inner wall of the flaring section is connected with the inner wall of the tube body through an inclined plane, the sampling cotton swab is arranged on the inclined plane in a supporting mode, and a cavity is formed in the tube cover. Internal threads are arranged on the inner wall of the bottom of the tube cover, sample lysate is arranged in the cavity, a pricking needle is arranged in the cavity, the top of the pricking needle penetrates through the top of the tube cover and is fixedly connected to a pricking needle push plate, and a C-shaped limiting part is clamped between the pricking needle push plate and the tube cover; the device not only facilitates the storage of samples, but also can improve the experiment efficiency; in addition, the collection tube is provided with zirconia beads for grinding, continuous mechanical friction force can be provided in the sample transportation process, and then the splitting decomposition effect on special pathogenic bacteria is improved. And the samples are directly conveyed in a sealed manner after being sampled, so that the risks of falling, misplacement and sample pollution are avoided.

The invention belongs to the technical field of health care, and particularly relates to isomaltooligosaccharide gel for preventing and treating gynecological genital tract inflammation and a preparation method of the isomaltooligosaccharide gel. The invention provides an isomaltooligosacharide gel for preventing and treating gynecological genital tract inflammation. The isomaltooligosacharide gel comprises isomaltooligosacharide, carbomer, gelatin, glycerol, triethanolamine, benzyl alcohol, phenoxyethanol and water. According to the invention, the isomaltooligosacharide, the carbomer and other components are specifically combined, so that the isomaltooligosacharide can maintain normal reproduction of vaginal probiotics. Therefore, when the isomaltooligosacharide gel provided by the invention is applied to the products for preventing and treating the gynecological genital tract inflammation, the occurrence of the gynecological genital tract inflammation can be reduced, red, swollen and pruritus can be quickly relieved, and pain can be reduced.

The application discloses a primer probe combination, a kit and application for detecting pathogenic microorganisms in a genital tract, wherein the primer probe combination comprises primer probe sequences shown in SEQ ID NO. 1-SEQ ID NO. 96, the pathogenic microorganisms in the genital tract include 27 pathogenic microorganisms which can cause diseases in the genital tract, such as Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis, Mycoplasma genitalium, Candida albicans, Candida glabrata, Candida tropicalis, Candida auris, Candida krusei, Candida dubliniensis and the like, and four common vaginal lactobacilli, such as Lactobacillus crispatus, Lactobacillus jensenii, Lactobacillus gasseri and Lactobacillus iners, and further include a human internal standard. Based on the fluorescence quantitative PCR technology, the 27 pathogenic microorganisms which can cause diseases in the genital tract and the four common vaginal lactobacilli can be simultaneously detected in an in-vitro sample, the main pathogenic microorganisms of the genital tract infection can be covered, the evaluation of the vaginal ecological environment can be satisfied, the detection time is shortened to about 40 minutes, and the specificity and the sensitivity are good.

1. The name of the design product: the pre-microscopy processing system. 2. The use of the design product: the pre-microscopy processing system is used for the processing of the human genital tract secretion sample swab in medical diagnosis. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: the design 1 perspective view. 5. Design 1 is designated as the basic design.